Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
Received 13 July 2012
Accepted for publication 9 August 2012
Published 24 September 2012 Volume 2012:5 Pages 199—211
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Federica Zoratto,1 Luigi Rossi,1 Angelo Zullo,2 Anselmo Papa,1 Eleonora Zaccarelli,1 Luigi Tomao,3 Erika Giordani,1 Maria Colonna,4 Giovanni Baiano,5 Silverio Tomao1
1Department of Medico-Surgical Sciences and Biotechnologies, “Sapienza” University, Oncology Unit, “SM Goretti” Hospital, Latina; 2Gastroenterology and Digestive Endoscopy Unit, “Nuovo Regina Margherita” Hospital, Rome; 3Biology Department, “Regina Elena National Cancer Institute”, Rome; 4Oncology Unit, “Don Luigi di Liegro” Hospital, Gaeta, 5Surgery Unit, “San Giovanni di Dio” Hospital, Fondi, Italy
Abstract: Colorectal cancer is one of the most common cancers worldwide. The prognosis of patients with metastatic colorectal cancer in recent years has increased from 5 months with best supportive care to nearly 2 years with chemotherapy combined with bevacizumab, an antivascular endothelial growth factor monoclonal antibody. New prognostic and predictive biomarkers have been identified to guide chemotherapy in metastatic colorectal cancer, such as KRAS and BRAF oncogenes. However, the status of these oncogenes does not affect the efficacy of bevacizumab, and biomarkers predicting response to treatment with bevacizumab are still lacking. Addition of bevacizumab to regimens based on fluoropyrimidines or irinotecan has been shown to improve overall survival in treatment-naïve patients with metastatic colorectal cancer. Similarly, a significant increase in overall survival rate is achieved by adding bevacizumab to fluoropyrimidines and oxaliplatin in patients with disease progression. Bevacizumab has been found to be effective even when used as third-line therapy and later. In addition, cohort studies have shown that bevacizumab improves survival significantly despite disease progression. Finally, bevacizumab therapy in the neoadjuvant setting for the treatment of liver metastasis is well tolerated, safe, and effective.
Keywords: metastatic colorectal cancer, bevacizumab, chemotherapy, biomarkers, liver metastases
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.